Long-Term Upside in Lilly's Alzheimer's Trial
2 months ago
Martin
"I just want to add and say that like I think I'm pretty excited to see how Lily's uh trial turns out as well. They're running a really long trial. Um I think uh Lily and Biogen both started really long-term clinical trials in Alzheimer's about five, six, seven years ago or something. And um know we hope to see actually a fiveyear topline readout in the near future."
The speaker expresses excitement about Lilly's long-term Alzheimer's trial, noting that both Lilly and Biogen initiated long-duration studies years ago. He points to a potential five‐year topline readout, suggesting that early intervention in Alzheimer's could offer substantial upside.
Scores
Alpha Potential
8.0/10
Novelty
7.0/10
Credibility
8.0/10
Timeliness
7.0/10
Overall
8.0/10
Sentiment
Bullish
Conviction
High
Tier
Company Commentary
Related Stocks
Episode Information
Episode:
Biotech Investors Brace for the Real Threat | End of Pharma | AVXL Erasing Data | Martin Shkreli
Source:
The Shkreli Pill
Published:
November 17, 2025
Idea Type:
Earnings Preview